Ligand Pharmaceuticals Incorporated
LGND
Rank in Stocks
#3112
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Share Price
$291.18
Last synced: 2026-07-31
Market Cap
$5.84B
Change (1 day)
-1.73%
Change (1 year)
55.93%
Country
US
Trade Ligand Pharmaceuticals Incorporated (LGND)
Category
Healthcare
P/B ratio for Ligand Pharmaceuticals Incorporated (LGND)
P/B ratio as of October 2026 TTM: 6.12
According to Ligand Pharmaceuticals Incorporated latest financial reports and stock price the company's current price-to-book ratio (TTM) is 6.12. At the end of 2023 the company had a P/B ratio of 1.76.
P/B ratio history for Ligand Pharmaceuticals Incorporated from 2000 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 6.12 | 159.20% |
| 2024 | 2.36 | 33.89% |
| 2023 | 1.76 | -6.54% |
| 2022 | 1.89 | -39.68% |
| 2021 | 3.13 | 37.81% |
| 2020 | 2.27 | -12.14% |
| 2019 | 2.58 | -55.62% |
| 2018 | 5.82 | -15.43% |
| 2017 | 6.88 | 20.53% |
| 2016 | 5.71 | -19.03% |
| 2015 | 7.05 | -82.93% |
| 2014 | 41.28 | 91.70% |
| 2013 | 21.54 | 43.98% |
| 2012 | 14.96 | -44.57% |
| 2011 | 26.99 | -207.83% |
| 2010 | -25.03 | -138.15% |
| 2009 | 65.60 | -359.82% |
| 2008 | -25.25 | -255.10% |
| 2007 | 16.28 | -49.56% |
| 2006 | 32.27 | -792.17% |
| 2005 | -4.66 | -59.06% |
| 2004 | -11.39 | -177.58% |
| 2003 | 14.68 | 369.28% |
| 2002 | 3.13 | -127.29% |
| 2001 | -11.46 | 29.98% |
| 2000 | -8.82 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | 2.19% |
US
|
|
| 13.2547 | 116.68% |
US
|
|
| 4.208 | -31.21% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 1.07% |
NL
|
